Preclinical studies in several animal models as well as clinical trials have shown a reduction in tumor growth following immunotherapy with interleukin-12 (IL-12). This cytokine is appropriate to test in therapeutic clinical trials to treat hepatocarcinoma (HC), a pathology often associated with hepatitis B or C-induced cirrhosis. The local delivery into the liver would be achieved through ex vivo gene transfer using retroviral (rv) vectors in autologous fibroblast carriers. In support of this clinical trial, a rv vector has been constructed to express coordinately both chains p35 and p40 of human IL-12. Here, we have tested good manufacturing practices (GMP) clinical lots of viral vectors derived from the transfected packaging cell line, PG13rvIL-12. We have also devised methods to facilitate the isolation of fibroblasts from freshly harvested skin specimens, enhance their outgrowth in large-scale cultures and assay IL-12 production following transduction, without any selection and irradiation. Twentyfour human skin specimens were processed to obtain fibroblast suspensions that were typically maintained for up to 8 or 12 passages. The mean ± s.d. overall time for obtaining the required number of transduced cells for the highest IL-12 need was 40 days. The procedure, in accordance with the French medical agency for gene therapy clinical trials, is now ready to begin a clinical trial.
Introduction
Hepatocarcinoma (HC) is the most frequent liver cancer with 250 000-1 000 000 new cases each year and represents the fourth leading cause of cancer death worldwide. Its incidence is increasing every year because of (i) an increase in life expectancy of patients presenting cirrhosis, (ii) improved diagnosis or treatment of hepatic diseases, and (iii) a higher frequency of the hepatic pathologies connected to the hepatitis C virus. [1] [2] [3] [4] The three curative treatments of HC are transplantation, resection and percutaneous destruction, 5 all of which improve the natural history of the HC and prolong the survival of patients with a unique tumor of less than 5 cm or a maximum of three lesions measuring at most 3 cm. In all other cases, however, these treatments become palliative. Thus, for about 90% of patients, no effective treatment can be proposed, 6 and HC remains a world health problem.
The heterodimeric cytokine interleukin 12 (IL-12) consists of two subunits, p40 and p35. 7 It is recognized as a master regulator of adaptive type 1 cell-mediated immunity, the critical pathway involved in protection against neoplasia and many viruses. 8 It enhances tumor destruction by activating cytotoxic T lymphocytes, priming the differentiation of naive CD4 þ T cells to helper T type 1 cells that can subsequently help tumor-specific cytotoxic T lymphocytes, and stimulating natural killer cells.
7,9-11 IL-12 presents immunomodulating and antiangiogenic functions, which have provided the rationale for exploiting this cytokine as an anticancer agent.
In this way, IL-12 has been applied as a recombinant protein in cancer patients in various phase I and II trials and found to show some efficacy. [12] [13] [14] [15] However, its use induced severe toxicity leading to the death of two patients in one phase II trial. 16, 17 On the basis of the promising results obtained in a large series of preclinical IL-12 gene therapy studies, 8 clinical trials have been designed with the aim of achieving cytokine production at the tumor site, while at the same time maintaining low serum concentrations to reduce systemic toxicity. [18] [19] [20] [21] Various strategies involving immune stimulation have shown occasional activity against HC leading to the execution of phase I immuno gene therapy involving IL-12 trials in relation to HC treatments. Sangro et al. 19, 20 and Mazzolini et al. 22 have evaluated the feasibility and safety of the intratumoral injection of an adenoviral vector encoding IL-12 or autologous dendritic cells transduced with an adenovirus encoding IL-12, respectively. They both concluded that although the two types of treatment are feasible and well tolerated, further studies are necessary to define and increase clinical efficacy.
Using an ex vivo gene therapy approach in a murine model of HC, we have shown earlier that ex vivo transduction of hepatocellular tumor cells or syngeneic fibroblasts with viral vectors showing long-lasting expression (retroviral (rv) vector encoding mIL-12), followed by subsequent intrahepatic injection, leads to tumor growth regression. This mIL-12 rv vector-mediated regression is associated with intrahepatic lobular inflammatory infiltration consisting of macrophages at an early stage, followed by CD4 T cells and CD8 T cells at a later stage. The IL-12 intrahepatic expression was well tolerated. This ex vivo gene therapy approach is highly clinically relevant and prompted us to propose it as a therapeutic option in patients with widespread liver cancer. 23, 24 Numerous clinical trials have involved the use of human fibroblasts as drug delivery systems. They can be used, for example, to cure diseases such as junctional epidermolysis bulbosa, 25 treat venous, diabetic and pressure ulcers by the release of growth factors or cytokines (vascular endothelial growth factor (VEGF), hepatocyte growth factor, basic fibroblast growth factor (FGF), transforming growth factor (TGF) b1 and IL-8), 26 increase tissue repair in acute or chronic wounds and in aesthetic and reconstructive surgery, 27 and treat Duchenne muscular dystrophy, 25 Alzheimer's disease 28 or cancer by the induction of an immune response. 21, 29 Fibroblasts are mostly obtained from skin biopsies varying in size from one clinical trial to another. 21, 28 They can be harvested by direct culture or enzymatic digestion of the biopsy, transduced using non-viral or viral vectors, selected with G418 28 and then extensively cultured to obtain a number of fibroblasts sufficient to produce the required drug dose. Cells have to be frozen and thawed without affecting their potency as drug vehicles and are mostly irradiated to ensure growth arrest.
The manufacture of biopsy-derived fibroblast culture is rigorous and complex, requiring adherence to good manufacturing practices and quality assurance. Some important considerations include ensuring asepsis, the prevention of contamination, cryopreservation of the cells and also maximizing the convenience of use by the physicians. The National (French) agency (AFSSAPS) and the European Medicinal Evaluation Agency (London, UK) have provided European standards for cell therapy.
In this report, we present the preclinical setting for a gene therapy protocol aimed at treating HC-bearing patients. We plan to inject sufficient fibroblasts to produce up to 300-5000 ng of IL-12 per 24 h. We adopted cell culture materials and methods approved by the French agency for cell and gene therapy (AFSSAPS) and by the European Medicinal Evaluation Agency. Accordingly, fibroblasts needed to be obtained and cultured without any antibiotics or enzymatic components, and then the selection of the transduced cells was forbidden. We have thereby changed the procedure described by Elder et al. 30 for the fibroblasts culture and developed a new packaging cell line to obtain viral vectors with a high titer to induce a better yield of transduced cells and not be obliged to use G418 selection.
Materials and methods

Specimens
Human skin was obtained from patients who underwent surgical resection of a tumor. In all, 5 to 10 cm 2 of tissue was excised. The tissue was placed in a wash medium consisting of Dulbecco's modified Eagle's medium (Cambrex Biosciences, LONZA, Verviers, Belgium) and incubated at room temperature for 30 min. The skin was trimmed of fat and connective tissue as well as the epidermal layer, and processed for the recovery of fibroblasts and culture.
Cell culture
Fibroblasts were mechanically disaggregated. The dermal tissue was sliced into 2 mm 2 pieces, which were either directly placed in culture as explants (20 pieces per 10 cm 2 plate) in Dulbecco's modified Eagle's medium (LONZA) supplemented with 10% human serum (HyClone, Perbio Sciences, Bre´bie`res, France), 0.1 mM non-essential amino acids (LONZA) and 2 mM glutamine (LONZA; fibroblast complete medium), or enzymatically digested in 600 UI ml À1 of collagenase I (Invitrogen, Cergy Pontoise, France) at 37 1C for 2 h and then grown in the fibroblast complete medium. Fibroblasts were grown with 10 ng ml À1 of human recombinant basic FGF-2 (R&D Systems Europe, Lille, France). PG13 (packaging cell lines, ATCC-CRL 10686) and HCT116 (colon carcinoma cell line, ATCC-CCL-247) cells, purchased from ATCC (American Type Culture Collection, Rockville, MD), were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (HyClone) and 2 mM glutamine. Fibroblast cultures were grown in 5% CO 2 , 95% humidity and were routinely passaged every 7 days after disaggregation with 0.25% irradiated porcine trypsin (HyClone) at room temperature for 2 min. The cells were routinely tested for mycoplasm contamination.
Fibroblasts were mitotically inactivated with 10 000 rads (1 rad ¼ 0.01 Gy) g-radiation.
PG13 transfection was performed using lipofectamin (Gibco/BRL, Invitrogen, Cergy Pontoise, France) as described by the supplier.
Retroviral transduction (crude extracts)
The MFG-GFP rv vector encoding the green fluorescent protein (GFP) gene was a generous gift of Genethon (Evry, France). The MFG-hIL-12 (crude or titered supernatants) vector containing both subunits of IL-12 is described below. The virus was harvested from confluent dishes of plasmid MFG (pMFG)-GFP transduced packaging PG13 cells (PG13rvGFP cells) or from pMFG-hIL-12 transduced PG13 packaging cells (PG13rvIL-12 cells), plated at a density of 5 Â 10 5 cells per 75 cm 2 dishes, every 12 h for 72 h, beginning 24 h after plating. Supernatants were filtered through 0.45 mm filters and kept at À80 1C.
Transduction of targeted cells was performed after thawing the undiluted supernatants at 37 1C. HCT116 or fibroblast target cells seeded in a 6-well plate (10 5 cells per well) were transduced by one, two or three cycles of exposure (depending on the experiment) to undiluted supernatant for 4 h in the presence of 5 mg ml À1 protamine sulfate (Sanofi, Toulouse, France).
Titration of rv vectors
Titrations were performed at the Genethon III using a quantitative real-time PCR method (TaqMan) to determine the active biological titer of the vector preparations as described earlier. 31 As a template, they used the gag sequence, common to all the vectors (forward primer: 5 0 -ATTGACTGAGTCGCCCGG-3 0 and reverse primer:
. Primers and probes used for the standardization of the infection were from albumine gene (Genbank accession number M12523): forward primer: 5 0 -GCTGT CATCTCTTGTGGGCTG-3 0 and reverse primer:
0 . HCT116 cells were infected with serial dilutions of the vectors, and genomic DNA was extracted after 48 h in the culture. Amplification reactions were performed according to the manufacturer's specifications (ABI Prism 7700 sequence detection system; Applied Biosystems, Courtaboeuf, France) with the primers and probes described and with an additional set of primers and probes into albumin to normalize for the genomic copy number. The amount of proviral DNA was measured by comparison with a plasmid standard curve.
Retroviral transduction (titered extracts)
Cultured human fibroblasts in the log phase of growth and in low culture passage (3) seeded in a 6-well plate (10 5 cells per well) were transduced by one, two or three cycles of exposure to viral vectors, depending on the experiment, for 4 h in the presence of 5 mg ml -1 protamine sulfate. Transduction was performed at an MOI (multiplicity of infection) of 10.
GFP detection
For fluorescence analyses, cells were trypsinized, washed twice with phosphate-buffered saline and fixed in phosphate-buffered saline containing 0.4% formaldehyde. Fluorescence activated cell sorting analysis was conducted on a Coulter XL 4C (Beckman Coulter, Roissy CDG, France) coupled with the system of acquisition software, WIN-MDI, 2.8.
IL-12 detection
Production of IL-12 by the transduced HCT116 cells or fibroblasts in culture was monitored by ELISA testing of culture supernatants (R&D Systems). The culture medium of transduced cells was collected every 2 days of culture post-transduction. The IL-12 concentration was determined by comparison with a standard curve prepared with recombinant IL-12. IL-12 concentration was expressed as ng per 24 h per 10 6 cells as described earlier. 30 Both irradiated and non-irradiated fibroblasts were tested.
Results
Establishment of human dermal fibroblast cultures
We used the same protocol that was described by Elder et al. 30 to initiate our fibroblast cultures. In the future clinical trial, we plan to use skin specimens of 10 cm 2 in size easily obtained under local anesthesia. The specimens we used (n ¼ 24) in the preclinical setting ranged from 5 to 10 cm 2 and generally originated from the abdomen. For the clinical protocol, we plan to use only fibroblasts derived from minced skins specimens. First, we need to verify that we could obtain as many fibroblasts using this technique as that obtained using collagenase, the technique used by Elder et al. 30 For this purpose, we divided five skin specimens (n ¼ 5) into two halves, one half for explant-derived culture and the other half for digest-derived culture (Figure 1a) .
After 3 weeks of cell culture, we obtained 1.5 more fibroblasts using the enzymatic method compared with the explant method ( Figure 1a) . However, in accordance with the French medical agency and the possibility of obtaining sufficient numbers of fibroblasts (4 Â 10 6 ± 0.6) for use in the clinical trial, we adopted the explant method as the routine method for the preparation of human dermal fibroblast cultures in our laboratory. Procedures and products used were approved by the French medical agency for gene therapy clinical trials. Whatever the method used, of 24 human fibroblast cultures initiated, 23 (95%) were successfully expanded and showed morphological characteristics consistent with dermal fibroblasts characterized earlier.
After 3 weeks of cell culture, two vials of 10 6 fibroblasts were frozen slowly to À80 1C. One vial of 10 6 cells was sent to verify the sterility of the cells (absence of fungi, bacteria or mycoplasma contaminants) and the remaining cells were plated at 1 Â 10 5 cells per T25 flasks. As the cells for the clinical trial will be kept at À80 1C and not in liquid nitrogen for at least 1 year, we checked the viability of the cells thawed from À80 1C or from À160 1C after 1-year conservation (n ¼ 10). As shown in Figure 1b , cells showed a very good recovery after maintenance either at À80 1C or À160 1C. We checked the amount of IL-12 produced by the cells (n ¼ 3) before and after thawing from À80 1C. Dosages were performed on 48 h supernatants of the cells on the day of freezing and 48 h after thawing. We observed a 5 ± 4% decrease of the synthesis of IL-12. IL-12 was continuously produced by these cells over the next 15 days (data not shown).
Transduction efficiency of the human dermal fibroblasts
The ex vivo strategy using fibroblasts transduced with a rv vector encoding hIL-12 has been validated earlier in Elaboration of an ex vivo gene therapy protocol B Lortal et al clinical trials of patients with cancer by both Lotze et al. 31 and Kang et al. 21 The two teams used the same rv vector, an MFG-based rv plasmid constructed by L Zitvogel et al., 33 containing the two subunits of IL-12 (p35 and p40) as well as the neomycin resistance selectable marker gene (NeoR). The viral particles were derived from the packaging cell line, cCRIP, 34 which gives recombinant retrovirus with amphotropic host ranges (env gene from the 4070A virus genome). In this trial, we plan to use a plasmid lacking the NeoR gene and not select the transduced fibroblasts before injection into the patients. For this purpose, we used the PG13 packaging cell line known to produce viral titers as high as the cCRIP cells (1 Â 10 6 vg ml À1 compared with 1 Â 10 5 vg ml À1 ). We also chose PG13 for safety reasons as no RCR had been noticed on supernatants obtained from PG13 packaging cell lines (http://ww.fda.gov/ohrms/dockets/AC/01/briefing/3739b1_01.htm) at the time we chose this cell line, whereas RCR had been noticed on supernatants obtained from PA317 or cCRIP cell lines. As cCRIP cells produce amphotropic 4070A pseudotyped viral vectors, whereas PG13 cells produce Gibbon-ape leukemia virus pseudotyped viral vector, 35 we verified that human fibroblasts could be efficiently transduced by this latter pseudotyped viral vector.
Crude supernatant from PG13rvGFP cells was used to transduce 1 Â 
Retroviral vectors
Replication-defective rv vectors expressing IL-12 under the transcriptional control of the long terminal repeat (LTR) promoter were constructed from the plasmid pTFG-hIL-12 ( Figure 3 ) 33 by deleting the Internal Ribosome Entry Site (IRES)-NeoR element through BamH1 digestion. This plasmid has been entirely sequenced. Compared with the original sequence of the two subunits encoding p40 and p35, this plasmid has a 12 nucleotide deletion in the 5 0 end of the p35 sequence allowing translation from the second in-frame ATG. This step has been performed at Genethon, which certified the clinical grade and produced a clinical lot of the plasmid.
Using lipofectamin, we cotransfected 10 5 PG13 cells (retrovirus packaging cell line based on the Gibbon-ape leukemia virus) with the pMFG-IL-12 plasmid (10 mg) and pcDNA3 (0.1 mg; Invitrogen). We then selected 96 G418 (0.5 mg ml À1 ) resistant PG13 cell clones and used their supernatants to transduce HCT116 cells. The supernatant from the transduced HCT116 cells was then tested 48 h later for the presence of human p70 hIL-12 by ELISA. Three clones of PG13rvIL-12 cells were selected on the basis of the secretion of IL-12 ( Figure 4a ) and sent to Genethon. These three clones were then tested for the viral titers (TaqMan method as described in Materials and Methods section) and the absence of bacterial, fungal and mycoplasma contamination. Clone no. 59 was selected on the basis of its sterility and titration of infectious particles by Taqman qPCR (6.6 Â 10 5 vg ml
À1
). Only one copy of the viral vector was detected in the cells. These cells have been amplified for a mini cell bank and their stability has been checked. The evolution of the viral titers with or without selection (0.5 mg G418) was tested over a period of 3 months. The viral titer was stable (1 Â 10 6 vg ml
) with selection but decreased rapidly (within 6 weeks) without selection. The viral vectors were undetectable after 3 months of culture without selection. 
Elaboration of an ex vivo gene therapy protocol B Lortal et al
Freezing and thawing rvIL-12-producing cells had no effect on the viral titers if the transfected PG13 cells were grown with a selective medium (with 0.5 mg ml À1 G418). PG13rvIL-12-producing cells were plated in Dulbecco's modified Eagle's medium supplemented with 10% serum. On the following day, the medium was changed for one containing various percentages of fetal calf serum, and supernatants containing rv vectors were harvested 48 h later. These supernatants were used to transduce human dermal fibroblasts, the supernatants of which were tested 48 h later for the presence of IL-12. As presented in Figure 4b , the supernatants of PG13rvIL-12 cells obtained with 0.5% serum gave the best IL-12-producing fibroblast cells.
We selected the PG13rvIL-12 cell clone 59 for the production of the master cell bank. It was first used for the synthesis of a preclinical lot of rv vectors encoding hIL-12 for the ex vivo setting presented below. This preclinical lot constituted 40 vials each containing 1 ml of rv vectors harvested 48 h after plating the PG13 cells (titers: 2.7 Â 10 5 vg ml Effect of irradiation on IL-12 production by the transduced fibroblasts cells after thawing Patients will not be treated immediately during the clinical trial, and their transduced IL-12-producing fibroblasts will be preserved. These will be frozen at À801C and preserved for at least 6 weeks awaiting the results of the detection of replication-competent retrovirus. We froze five different IL-12-producing fibroblasts for a period of 2 months, thawed them and re-established them in culture for 3 days. The cells were then divided between two 12-well plates (10 000 cells per well). The following day, one of the two plates was irradiated for a total of 10 000 rads. We chose this dose on the basis of earlier observations (data not shown) of two clones of melanoma cells obtained from a skin biopsy surviving 5000 rads of irradiation. As shown in Figure 5a , all irradiated fibroblasts failed to proliferate. We wished to verify their continued ability to produce IL-12. For this purpose, we changed the medium of the cells at day 4 postirradiation and checked for IL-12 production at day 6. This also allowed us to ensure a continued production of IL-12 over a minimum period of 6 days postirradiation in line with our intended program of three injections of fibroblasts every 7 days during the clinical trial. At the same time, and under the same conditions, we checked the IL-12 production of the non-irradiated transduced fibroblasts. As can be seen in Figure 5b , IL-12 was produced for at least 6 days postirradiation and in greater amounts following irradiation compared with that produced by non-irradiated cells.
In sum, our results confirm the data published by Elder et al. 30 that autologous fibroblasts are a reliable and convenient vehicle for the delivery of drugs such as cytokine IL-12 into HC tumors. In addition, our data show the possibility of obtaining and expanding cells without enzymatic treatment and generating efficient IL-12-producing cells without G418 selection.
Discussion
Cell therapy represents the last frontier of a therapeutic approach that began almost 40 years ago to cure diseases caused by the defective functioning of specific cell types. Since then, the transplantation of 'healthy cells' has become standard therapy not only for hematopoietic Elaboration of an ex vivo gene therapy protocol B Lortal et al disorders, but also for acquired skin, heart or bone damage, 25, 36 and more recently, for use as potent drug delivery vehicles. 27 Several cell types can be used as drug vehicles (keratinocytes, bone marrow-derived mesemchymal stem cells, hepatocytes, dendritic cell and fibroblasts) 21 ,37-39 but more and more frequently, however, primary cells must be extensively processed ex vivo before they can be used as pharmaceutical tools. Using fibroblasts as drug delivery systems in HC treatment offers distinct, clinically relevant advantages over in vivo techniques, including (1) its nondependence on transfection efficiency, which may vary in vivo; (2) the possibility of avoiding the delivery of infectious viral particles to the host; (3) the exclusion of all potential immunogens other than the nominal tumor antigen, (4) knowledge of the exact expression of IL-12 before injection, which can be tailored at will depending on the number of cells injected and (5) the irradiation of genetically modified fibroblasts before injection, thereby abrogating unwanted long-term transgene expression.
Furthermore, the therapeutic genetically modified autologous fibroblasts used in this technique have already been validated in two clinical trials. 21 Elder et al. 30 have earlier shown the successful culturing, expansion and genetic modification of human fibroblasts to produce IL-4 and IL-12. They also showed that dermal fibroblasts can be easily obtained and cultured from nearly all individuals using a simple procedure combining hyaluronidase and collagenase treatment. Once in culture and transduced with rv vectors, the cells were selected for IL-12 expression using a cotransfected NeoR gene conferring resistance to geneticin (G418). This procedure (G418 selection after transduction of the targeted cells) has been used in several clinical trials. 21, 28 French legislation in accordance with the European Medical Agency (http://emea.europa.eu/) forbids the use of gene-conferring resistance to antibiotics such as geneticin and strongly dissuades from the use of enzymatic digestion of dermal biopsies. For these reasons, we adapted the protocol used by Elder et al. 30 to be in accordance with European legislation. In the same way, all the products (media, chemicals including protamin sulfate, porcine trypsin and human serum) were selected in accordance with European legislation for their future use in clinical trials of cellular or gene therapy in Europe. The viral vectors were synthesized according to the legislation and their methods of generation used by Genethon were approved by the AFSSAPS (French agency for the sanitary safety of health products).
In the future clinical trials, we plan to include 15 cirrhotic patients bearing an HC nonaccessible to conventional treatment. This will be an open-label, nonrandomized, dose escalation phase I trial with the number of fibroblasts injected adjusted according to the desired IL-12 dose, that is, 100 ng per 24 h for the first three patients, then 300, 1000, 3000 and 5000 ng per 24 h, respectively, for the remaining four sets of three patients. Autologous fibroblasts will be obtained from a skin biopsy. The sizes of skin biopsies described in the literature vary from 3 28 to 20 cm 2 . 21 A biopsy of up to 10 cm 2 could be obtained with local anesthesia. This study has shown the possibility of obtaining sufficient fibroblasts (4 Â 10 6 cells) after 3 weeks of culture from a 10 cm 2 biopsy and without any enzymatic digestion to be able to (1) send cells to the laboratory to verify the sterility of the cells (bacterial, viral or mycoplasma contamination); (2) freeze three vials each containing 10 6 cells, enough to re-initiate a cell culture without a second biopsy from the patient and (3) six T80 plates each with 1 Â 10 5 cells for transduction over the following days. For each fibroblast culture, we initiated five T80 plates of fibroblasts and kept the last one as a control of cell viability in this preclinical setting.
In the clinical trial, the cells will be transduced ex vivo three times on three consecutive days by means of the rv vectors described below and as has already been performed in other clinical trials using MFG-derived rv vectors. 40 We checked any gain in the number of transduced cells using three rounds of transduction instead of one. We noticed no gain from transducing the fibroblasts three times; however, three rounds could increase the number of copies of integrated vector by 1.5-fold (Genethon III, personnel communication). For this reason, Genethon III will provide a clinical-grade rv vector (titer 5 Â 10 6 vg ml
À1
) in a sterile bag containing 50 ml of viral vectors. The cells will receive 10 ml of viral vectors each day for 3 days. The yield of transfection under these conditions as verified during this preclinical trial is estimated at roughly 80%. The cells will then be amplified.
In this preclinical trial, we checked the feasibility of generating sufficient amounts of genetically modified fibroblasts required for the upper dose (5000 ng of IL-12 every 24 h). Considering that the cells expressed roughly 10 ng per 10 6 cells every 24 h and 5 Â 10 8 cells per injection are thus needed. As at least three injections must be administered in the clinical trial, 1.5 Â 10 9 cells are needed. This number of cells was achieved within 2 months of culture with 10 ng ml À1 FGF-2. The culture time was inferior for lower doses of IL-12 required for the patients.
For the clinical trial, as soon as the total number of fibroblasts is obtained, 10 6 genetically modified fibroblasts will be sent to Genosafe (Evry, France), whereas the rest of the total fibroblast culture will be frozen. Genosafe will perform the tests to ensure that the human fibroblasts contain no replication-competent rv vectors (among others the Mus dunni test). We tested the recovery of the cells after freezing and thawing at À80 1C. Indeed, as rv transduction must be performed in a negative pressurized laboratory and as cells to be injected into patients must be cultured in a laboratory with positive pressure, we needed to construct a laboratory with positive pressure as part of one with negative pressure. In such a structure, we had no separate room to stock liquid nitrogen. We, therefore, needed to freeze cells at À80 1C. We verified that genetically modified cells could be maintained at this temperature.
Once Genosafe have confirmed the safety of the cells, genetically modified cells will be thawed and cultured for 3 days. This feasibility of freezing and thawing has been verified in this preclinical study with a recovery of viable cells of roughly 80%. We checked the amount of IL-12 synthesized by the cells before and after thawing. We noticed a 5±4% decrease in IL-12 production. This decrease needs to be taken into account in future clinical trials.
An ELISA test will then be performed to adjust the number of fibroblasts to the amount of IL-12 required for the patients. Fibroblasts will be trypsinized and the amount of fibroblasts matching the requirement for IL-12 diluted in saline to a final volume of at least 20% that of the lesion to be injected and put into a syringe. In addition, a culture plate containing 10 5 fibroblasts will be plated. Both syringe and plate will be irradiated (10 000 rads). The cells in the syringe will then be administered using a 22-gauge fine needle placed under ultrasound guidance. Irradiation abrogates the risk of uncontrolled proliferation of transformed fibroblasts consecutive to a potential integration of the retrovirus in a sensitive zone of the genome. We noticed an important increase in the production of IL-12 after irradiation. This effect of irradiation on IL-12 production could be explained by the cytokine leakage from radiation-damaged cells or by a radiation-induced activation of transcription factors. 41, 42 This effect on cytokine production seems to be cell-or cytokine-dependent as Rosenthal et al. 43 reported a five-fold increase in granulocyte-macrophage colony-stimulating factor production after irradiation of genetically modified murine cells, whereas Moret-Tatay et al. 44 reported a decay in RNA production in genetically (granulocyte-macrophage colony-stimulating factor) modified tumor cells. Santin et al. 45 reported no effect of irradiation on IL-12 production by the genetically modified human ovarian tumor cells. As irradiation has been shown to increase the synthesis of IL-12 by the fibroblasts, the remaining fibroblasts in culture will be kept at 37 1C per 5% CO 2 . Fibroblast supernatants will be tested daily by ELISA to calculate the amount of IL-12 synthesized by the irradiated cells.
We are now ready to begin a clinical trial in which the main objectives will be (1) to assess the feasibility and safety of the transparietal route of implanting genetically modified fibroblasts into the liver and (2) to estimate the hepatic toxicity of the local production (intratumoral) of IL-12 and to determine the maximum tolerated dose and dose-limiting toxicity of genetically modified fibroblasts when administered as described. The secondary objectives are (1) to measure the therapeutic effect both locally and at a distance; (2) to estimate the intrahepatic and general immune response; (3) to estimate the systemic tolerance of the intrahepatic administration of IL-12-producing fibroblasts and (4) to measure the antiviral therapeutic effect in patients infected by hepatitis C.
